Arbekacin
- Generic Name
- Arbekacin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H44N6O10
- CAS Number
- 51025-85-5
- Unique Ingredient Identifier
- G7V6SLI20L
- Background
An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).
- Indication
Arbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02459158
Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01961830
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Kobe University
- Target Recruit Count
- 21
- Registration Number
- NCT01918384
- Locations
- 🇯🇵
Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
🇯🇵Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
🇯🇵National center of neurology and psychiatry, Kodaira, Tokyo, Japan
Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: ME1100 placebo inhalation solution
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT01907776
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
- Conditions
- Infection Due to Resistant Organism
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Registration Number
- NCT01659515
- Locations
- 🇺🇸
Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.